CeramTec appoints Dr. Hadi Saleh as new Chief Executive Officer
CeramTec Group (“CeramTec” or “the company”), a leading international producer of technical ceramics, is pleased to announce the appointment of Dr. Hadi Saleh as Chief Executive Officer. Formerly the company’s President Medical, Dr. Saleh will assume his new position immediately. The appointment comes after Henri Steinmetz, CeramTec’s Chief Executive Officer since 2016, has left the company with the full mutual agreement of the supervisory board.
Dr. Günter von Au, Chairman of CeramTec's supervisory board, said: “As the Group's President Medical, Dr. Hadi Saleh has demonstrated his professional expertise and outstanding leadership qualities. We are confident that under his guidance the CeramTec Group will continue its growth trajectory. At the same time, we thank Henri Steinmetz for his successful tenure at the company’s helm and wish him all the very best for the future, both professionally and personally.”
Dr. Hadi Saleh said: “I would like to maintain and build on the successful growth strategy that we have adopted and further strengthen CeramTec’s competitive position as a global leader in the technical ceramics sector. Looking forward to the coming years, we want the group to continue growing, both organically and through acquisitions. Our strategic goal is to turn the company from a German technology leader into a global market leader for innovative materials.”
In his previous role as President Medical, Dr. Saleh oversaw the group’s entire range of medical products and was co-responsible for its industrial business. Before joining CeramTec in July 2015, he held management positions at US medical technology company Biomet, one of the world’s largest suppliers of orthopedic implants, for over ten years.
Acquisition closed
In October 2017 it was announced that CeramTec was to be acquired by a consortium of investors led by funds advised by BC Partners and including the Public Sector Pension Investment Board and Ontario Teachers’ Pension Plan. The transaction has since received antitrust clearance and was completed on March 8, 2018.